Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases
Curation statements for this article:-
Curated by eLife
eLife assessment
This study presents a valuable finding on the identification of tumor-reactive T lymphocytes (TRLs) using paired single-cell sequencing and PDX models for cell therapy and marker selection in uveal melanoma treatment. The evidence supporting the claims of the authors is convincing, although the inclusion of detailed explanations of the results for a broader audience would have strengthened the study. The work will be of interest to clinicians and medical biologists working on uveal melanoma (UM).
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
- Cancer Biology (eLife)
Abstract
Uveal melanoma (UM) is a rare melanoma originating in the eye’s uvea, with 50% of patients experiencing metastasis predominantly in the liver. In contrast to cutaneous melanoma, there is only a limited effectiveness of combined immune checkpoint therapies, and half of patients succumb to recurrent disease after two years. This study aimed to provide a path towards enhancing immunotherapy efficacy by identifying and functionally validating tumor-reactive T cells in liver metastases of patients with UM. We employed single-cell RNA sequencing of biopsies and tumor-infiltrating lymphocytes (TILs) to identify potential tumor-reactive T cells. Patient-derived xenograft (PDX) models of UM metastases were created from patients, and tumor sphere cultures were generated from these models for co-culture with autologous or MART1-specific HLA-matched allogenic TILs. Activated T cells were subjected to TCR sequencing, and the TCRs were matched to those found in single-cell sequencing data from biopsies and expanded TILs. Our findings revealed that tumor-reactive T cells resided not only among activated and exhausted subsets of T cells, but also in a subset of cytotoxic effector cells. In conclusion, combining single-cell sequencing and functional analysis provides valuable insights into which T cells in UM may be useful for cell therapy amplification and marker selection.
Article activity feed
-
Author Response
Reviewer #1 (Public Review):
Summary:
This work successfully identified and validated TRLs in hepatic metastatic uveal melanoma, providing new horizons for enhanced immunotherapy. Uveal melanoma is a highly metastatic cancer that, unlike cutaneous melanoma, has a limited effect on immune checkpoint responses, and thus there is a lack of formal clinical treatment for metastatic UM. In this manuscript, the authors described the immune microenvironmental profile of hepatic metastatic uveal melanoma by sc-RNAseq, TCR-seq, and PDX models. Firstly, they identified and defined the phenotypes of tumor-reactive T lymphocytes (TRLs). Moreover, they validated the activity of TILs by in vivo PDX modeling as well as in vitro co-culture of 3D tumorsphere cultures and autologous TILs. Additionally, the authors found that TRLs are …
Author Response
Reviewer #1 (Public Review):
Summary:
This work successfully identified and validated TRLs in hepatic metastatic uveal melanoma, providing new horizons for enhanced immunotherapy. Uveal melanoma is a highly metastatic cancer that, unlike cutaneous melanoma, has a limited effect on immune checkpoint responses, and thus there is a lack of formal clinical treatment for metastatic UM. In this manuscript, the authors described the immune microenvironmental profile of hepatic metastatic uveal melanoma by sc-RNAseq, TCR-seq, and PDX models. Firstly, they identified and defined the phenotypes of tumor-reactive T lymphocytes (TRLs). Moreover, they validated the activity of TILs by in vivo PDX modeling as well as in vitro co-culture of 3D tumorsphere cultures and autologous TILs. Additionally, the authors found that TRLs are mainly derived from depleted and late-activated T cells, which recognize melanoma antigens and tumor-specific antigens. Most importantly, they identified TRLs-associated phenotypes, which provide new avenues for targeting expanded T cells to improve cellular and immune checkpoint immunotherapy.
Strengths:
Jonas A. Nilsson, et al. has been working on new therapies for melanoma. The team has also previously performed the most comprehensive genome-wide analysis of uveal melanoma available, presenting the latest insights into metastatic disease. In this work, the authors performed paired sc-RNAseq and TCR-seq on 14 patients with metastatic UM, which is the largest single-cell map of metastatic UM available. This provides huge data support for other studies of metastatic UM.
We thank the reviewer for these kind words about our work.
Weaknesses:
Although the paper does have strengths in principle, the weaknesses of the paper are that these strengths are not directly demonstrated. That is, insufficient analyses are performed to fully support the key claims in the manuscript by the data presented. In particular：
The author's description of the overall results of the article should be logical, not just a description of the observed phenomena. For example, the presentation related to the results of TRLs lacked logic. In addition, the title of the article emphasizes the three subtypes of hepatic metastatic UM TRLs, but these three subtypes are not specifically discussed in the results as well as the discussion section. The title of the article is not a very comprehensive generalization and should be carefully considered by the authors.
We thank the reviewer for the critical reading of our work. We agree that there is need of more discussion and will do this in a revised version.
The authors' claim that they are the first to use autologous TILs and sc-RNAseq to study immunotherapy needs to be supported by the corresponding literature to be more convincing. This can help the reader to understand the innovation and importance of the methodology.
We will go through the manuscript and literature to see where there might be missing references.
In addition, the authors argue that TILs from metastatic UM can kill tumor cells. This is the key and bridging point to the main conclusion of the article. Therefore, the credibility of this conclusion should be considered. Metastatic UM1 and UM9 remain responsive to autologous tumors under in vitro conditions with their autologous TILs.
UM1 responds also in vivo in the subcutaneous model in the paper. We have also finished an experiment where we show that this model also responds in a liver metastasis model. These data will be added in next version of the paper.
In contrast, UM22, also as a metastatic UM, did not respond to TIL treatment. In particular, the presence of MART1-responsive TILs. The reliability of the results obtained by the authors in the model of only one case of UM22 liver metastasis should be considered. The authors should likewise consider whether such a specific cellular taxon might also exist in other patients with metastatic UM, producing an immune response to tumor cells. The results would be more comprehensive if supported by relevant data.
The reviewer has interpreted the results absolutely right, the allogenic and autologous MART1-specific TILs cells while reactive in vitro against UM22, cannot kill this tumor either in a subcutaneous or liver metastases model. We hypothesize this has to do with an immune exclusion phenotype and show weak immunohistochemistry that suggest this. We hope the addition of more UM1 data can be viewed as supportive of tumor-reactivity also in vivo.
In addition, the authors in that study used previously frozen biopsy samples for TCR-seq, which may be associated with low-quality sequencing data, high risk of outcome indicators, and unfriendly access to immune cell information. The existence of these problems and the reliability of the results should be considered. If special processing of TCR-seq data from frozen samples was performed, this should also be accounted for.
We agree with the reviewers and acknowledge we never anticipated the development of single-cell sequencing techniques when we started biobank 2013. We performed dead cell removal before the 10x Genomics experiment. We have also done extensive quality controls and believe that the data from the biopsies should be viewed as a whole and that quantitative intra-patient comparisons cannot be done.
Reviewer #2 (Public Review):
Summary:
The study's goal is to characterize and validate tumor-reactive T cells in liver metastases of uveal melanoma (UM), which could contribute to enhancing immunotherapy for these patients. The authors used single-cell RNA and TCR sequencing to find potential tumor-reactive T cells and then used patient-derived xenograft (PDX) models and tumor sphere cultures for functional analysis. They discovered that tumor-reactive T cells exist in activated/exhausted T cell subsets and in cytotoxic effector cells. Functional experiments with isolated TILs show that they are capable of killing UM cells in vivo and ex vivo.
Strengths:
The study highlights the potential of using single-cell sequencing and functional analysis to identify T cells that can be useful for cell therapy and marker selection in UM treatment. This is important and novel as conventional immune checkpoint therapies are not highly effective in treating UM. Additionally, the study's strength lies in its validation of findings through functional assays, which underscores the clinical relevance of the research.
We thank the reviewer for these kind words about our work.
Weaknesses:
The manuscript may pose challenges for individuals with limited knowledge of single-cell analysis and immunology markers, making it less accessible to a broader audience.
The first draft of the manuscript (excluding methods) was written by a person (J.A.N) who is not a bioinformatician. It has been corrected to include the correct nomenclature where applicable but overall it is written with the aim to be understandable. We will make an additional effort for the next version.
-
-
-
eLife assessment
This study presents a valuable finding on the identification of tumor-reactive T lymphocytes (TRLs) using paired single-cell sequencing and PDX models for cell therapy and marker selection in uveal melanoma treatment. The evidence supporting the claims of the authors is convincing, although the inclusion of detailed explanations of the results for a broader audience would have strengthened the study. The work will be of interest to clinicians and medical biologists working on uveal melanoma (UM).
-
Reviewer #1 (Public Review):
Summary:
This work successfully identified and validated TRLs in hepatic metastatic uveal melanoma, providing new horizons for enhanced immunotherapy. Uveal melanoma is a highly metastatic cancer that, unlike cutaneous melanoma, has a limited effect on immune checkpoint responses, and thus there is a lack of formal clinical treatment for metastatic UM. In this manuscript, the authors described the immune microenvironmental profile of hepatic metastatic uveal melanoma by sc-RNAseq, TCR-seq, and PDX models. Firstly, they identified and defined the phenotypes of tumor-reactive T lymphocytes (TRLs). Moreover, they validated the activity of TILs by in vivo PDX modeling as well as in vitro co-culture of 3D tumorsphere cultures and autologous TILs. Additionally, the authors found that TRLs are mainly derived from …Reviewer #1 (Public Review):
Summary:
This work successfully identified and validated TRLs in hepatic metastatic uveal melanoma, providing new horizons for enhanced immunotherapy. Uveal melanoma is a highly metastatic cancer that, unlike cutaneous melanoma, has a limited effect on immune checkpoint responses, and thus there is a lack of formal clinical treatment for metastatic UM. In this manuscript, the authors described the immune microenvironmental profile of hepatic metastatic uveal melanoma by sc-RNAseq, TCR-seq, and PDX models. Firstly, they identified and defined the phenotypes of tumor-reactive T lymphocytes (TRLs). Moreover, they validated the activity of TILs by in vivo PDX modeling as well as in vitro co-culture of 3D tumorsphere cultures and autologous TILs. Additionally, the authors found that TRLs are mainly derived from depleted and late-activated T cells, which recognize melanoma antigens and tumor-specific antigens. Most importantly, they identified TRLs-associated phenotypes, which provide new avenues for targeting expanded T cells to improve cellular and immune checkpoint immunotherapy.Strengths:
Jonas A. Nilsson, et al. has been working on new therapies for melanoma. The team has also previously performed the most comprehensive genome-wide analysis of uveal melanoma available, presenting the latest insights into metastatic disease. In this work, the authors performed paired sc-RNAseq and TCR-seq on 14 patients with metastatic UM, which is the largest single-cell map of metastatic UM available. This provides huge data support for other studies of metastatic UM.Weaknesses:
Although the paper does have strengths in principle, the weaknesses of the paper are that these strengths are not directly demonstrated. That is, insufficient analyses are performed to fully support the key claims in the manuscript by the data presented. In particular：The author's description of the overall results of the article should be logical, not just a description of the observed phenomena. For example, the presentation related to the results of TRLs lacked logic. In addition, the title of the article emphasizes the three subtypes of hepatic metastatic UM TRLs, but these three subtypes are not specifically discussed in the results as well as the discussion section. The title of the article is not a very comprehensive generalization and should be carefully considered by the authors.
The authors' claim that they are the first to use autologous TILs and sc-RNAseq to study immunotherapy needs to be supported by the corresponding literature to be more convincing. This can help the reader to understand the innovation and importance of the methodology. In addition, the authors argue that TILs from metastatic UM can kill tumor cells. This is the key and bridging point to the main conclusion of the article. Therefore, the credibility of this conclusion should be considered. Metastatic UM1 and UM9 remain responsive to autologous tumors under in vitro conditions with their autologous TILs. In contrast, UM22, also as a metastatic UM, did not respond to TIL treatment. In particular, the presence of MART1-responsive TILs. The reliability of the results obtained by the authors in the model of only one case of UM22 liver metastasis should be considered. The authors should likewise consider whether such a specific cellular taxon might also exist in other patients with metastatic UM, producing an immune response to tumor cells. The results would be more comprehensive if supported by relevant data.
In addition, the authors in that study used previously frozen biopsy samples for TCR-seq, which may be associated with low-quality sequencing data, high risk of outcome indicators, and unfriendly access to immune cell information. The existence of these problems and the reliability of the results should be considered. If special processing of TCR-seq data from frozen samples was performed, this should also be accounted for.
-
Reviewer #2 (Public Review):
Summary:
The study's goal is to characterize and validate tumor-reactive T cells in liver metastases of uveal melanoma (UM), which could contribute to enhancing immunotherapy for these patients. The authors used single-cell RNA and TCR sequencing to find potential tumor-reactive T cells and then used patient-derived xenograft (PDX) models and tumor sphere cultures for functional analysis. They discovered that tumor-reactive T cells exist in activated/exhausted T cell subsets and in cytotoxic effector cells. Functional experiments with isolated TILs show that they are capable of killing UM cells in vivo and ex vivo.Strengths:
The study highlights the potential of using single-cell sequencing and functional analysis to identify T cells that can be useful for cell therapy and marker selection in UM treatment. …Reviewer #2 (Public Review):
Summary:
The study's goal is to characterize and validate tumor-reactive T cells in liver metastases of uveal melanoma (UM), which could contribute to enhancing immunotherapy for these patients. The authors used single-cell RNA and TCR sequencing to find potential tumor-reactive T cells and then used patient-derived xenograft (PDX) models and tumor sphere cultures for functional analysis. They discovered that tumor-reactive T cells exist in activated/exhausted T cell subsets and in cytotoxic effector cells. Functional experiments with isolated TILs show that they are capable of killing UM cells in vivo and ex vivo.Strengths:
The study highlights the potential of using single-cell sequencing and functional analysis to identify T cells that can be useful for cell therapy and marker selection in UM treatment. This is important and novel as conventional immune checkpoint therapies are not highly effective in treating UM. Additionally, the study's strength lies in its validation of findings through functional assays, which underscores the clinical relevance of the research.Weaknesses:
The manuscript may pose challenges for individuals with limited knowledge of single-cell analysis and immunology markers, making it less accessible to a broader audience. -
